Wang, Jun-Sing

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 3,163

The power of genetic diversity in genome-wide association studies of lipids

Graham, S. E., Clarke, S. L., Wu, K.-H. H., Kanoni, S., Zajac, G. J. M., Ramdas, S., Surakka, I., Ntalla, I., Vedantam, S., Winkler, T. W., et al. (2021) · Nature

Genetic Associations and EpidemiologyLipoproteins and Cardiovascular Health

Cited by 972

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 638

Levels of serum high mobility group box 1 were independently associated with cardiovascular risk in patients undergoing coronary angiography

Wang, J.-S., Sheu, W. H.-H., Lee, W.-J., Lee, I.-T., Lin, S.-Y., Lee, W.-L., Liang, K.-W., & Lin, S.-J. (2018) · Clinica Chimica Acta

Advanced Glycation End Products researchDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 5